New clinical data surrounding Retatrutide , specifically the high-dose formulation branded as ZPHC, suggest a considerable impact on weight decrease and associated metabolic factors. Researchers posit that this dual agonist , affecting both GLP-1 and GIP systems, has the potential to provide a m